Table 5.

Neutralization of interleukin (IL)-10 modified stimulatory molecules on CD3^– CD56⁺ cells from patients with advanced tuberculosis (A-TB)

	MFI
PBMC incubated with	CD16	CD11a	% CD69+ cells
–	178 ± 27	190 ± 48	14 ± 5
anti-IL-10	232 ± 30*	315 ± 40*	14 ± 6
M.tb	165 ± 36	162 ± 31	16 ± 5
M.tb + anti-IL-10	206 ± 47*	290 ± 46*	30 ± 6*
M.tb + IL-15	219 ± 50	250 ± 35	56 ± 6
M.tb + IL-15 + anti-IL-10	204 ± 31	310 ± 57	55 ± 6
M.tb + IL-18	171 ± 36	250 ± 38	25 ± 5
M.tb + IL-18 + anti-IL-10	166 ± 26	270 ± 46	28 ± 6

Peripheral blood mononuclear cells (PBMC) from four patients with advanced tuberculosis (A-TB) were incubated in complete medium (–) or Mycobacterium tuberculosis (M.tb) in the presence or absence of interleukin (IL)-15 or IL-18, with or without anti-IL-10, for 24 hr and cell surface expression of CD16, CD69 or CD11a on CD3^– CD56⁺ cells was analysed by flow cytometry. Mean fluorescence intensity (MFI) for CD16 and CD11a molecules and the percentage of CD69⁺ cells are shown. Results are expressed as mean ± standard error of the mean (SEM). Statistical differences: PBMC + anti-IL10 versus PBMC without anti-IL-10:

^*P < 0·05.